Immune Mechanisms Underlying the Neuroprotective Effects of Physical Activity in Human and Mouse Models of Genetic Risk for Alzheimers Disease

在阿尔茨海默病遗传风险的人类和小鼠模型中,体力活动的神经保护作用背后的免疫机制

基本信息

  • 批准号:
    10164687
  • 负责人:
  • 金额:
    $ 153.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-05-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

Abstract The APOE ϵ4 allele is the most important genetic risk factor for late onset Alzheimer's disease (AD). APOE ϵ4 may contribute to AD risk by altering inflammation, lipid homeostasis and/or amyloid clearance. Recent genetics studies have implicated multiple pathways in innate immunity in late-onset AD, including the triggering receptor expressed on the myeloid cells 2 (TREM2) gene. In contrast, exercise and physical activity (PA) produce anti-inflammatory changes in the periphery and neurogenic, angiogenic, and anti-inflammatory brain changes in animals. The mechanistic relationships between APOE, innate immunity, and AD, and the potential moderating influence of PA, remain to be established. Our published data on cognitively intact, healthy elders followed for 18 months indicate that sedentary ϵ4 carriers demonstrate significantly lower fMRI activation, poorer episodic memory performance, smaller hippocampal volumes, and abnormal white matter diffusion compared to ϵ4 carriers who engage in regular PA. Most importantly, these group differences were not observed between low and high PA non-carriers, suggesting that the neuroprotective effects of PA are especially potent for persons at genetic risk for AD. Additional preliminary studies demonstrate that TREM2+ innate immune cells play a direct role in regulating AD pathologies in both animal models of AD and potentially in human AD patients. For the proposed interdisciplinary project, our overall hypothesis posits that PA counteracts the negative inflammatory effects of the ϵ4 allele, affecting TREM2 and other innate immune pathways implicated in AD, thereby reducing the risk of cognitive decline and AD in ϵ4 carriers. This project has two specific aims. Aim 1 will recruit 150 cognitively intact, healthy elders (ages 65-80): 75 APOE ϵ4 carriers (ϵ3/ϵ4) and 75 ϵ4 non-carriers (ϵ3/ϵ3). Participants will undergo state-of-the-art measurements of PA and fitness; structural and functional 3T MRI; amyloid PET imaging; CSF/blood biomarkers related to AD, inflammation, and exercise; and comprehensive memory/cognition testing on two occasions separated by 24- months. Aim 2 is analogous to the human project and will determine the impact of voluntary wheel running PA across age (3 months, 6 months, and 9 months) in novel transgenic mouse models of AD humanized for ϵ3 and ϵ4 and crossed with APPPS1 (APPPS1; APOE3/3 and APPPS1; APOE4/4) and control strains. Key indices include: TREM2+ cells, expression of proinflammatory markers, brain Aβ42, and spatial memory performance. Together, these complementary human and animal studies will provide key insights into potential mechanisms linking APOE genotype, exercise, inflammation, AD brain pathology, and cognition that could ultimately be targeted therapeutically.
摘要 APOE β 4等位基因是晚发性阿尔茨海默病(AD)最重要的遗传危险因素。载脂蛋白E β 4 可能通过改变炎症、脂质稳态和/或淀粉样蛋白清除而导致AD风险。最近 遗传学研究表明,迟发性AD的先天免疫中存在多种途径,包括触发 髓样细胞受体2(TREM 2)基因。运动和体力活动(PA) 在外周和神经源性、血管生成性和抗炎性大脑中产生抗炎性变化 动物的变化。载脂蛋白E、先天免疫和AD之间的机制关系, 但是,要想发挥人民军的缓和作用,还有待建立。我们发表的关于认知完整的健康老年人的数据 18个月的随访结果表明,久坐的β 4携带者表现出明显较低的fMRI激活, 情节记忆表现较差,海马体积较小,白色物质扩散异常 与从事常规PA的104名运营商相比。最重要的是,这些群体差异并不是 在低PA和高PA非携带者之间观察到,这表明PA的神经保护作用是 特别是对AD遗传风险人群有效。其他初步研究表明,TREM 2 + 先天性免疫细胞在调节AD动物模型和潜在的AD病理中起直接作用, 在人类AD患者中。对于拟议的跨学科项目,我们的总体假设是PA 抵消了TREM 4等位基因的负面炎症效应,影响TREM 2和其他先天免疫 参与AD的途径,从而降低AD 4携带者的认知能力下降和AD的风险。这个项目 有两个具体目标。目标1将招募150名认知功能完整的健康老年人(年龄65-80岁):75 APOE ≥ 4 携带者(103/104)和75/104非携带者(103/103)。参与者将接受最先进的PA测量 和健身;结构和功能3 T MRI;淀粉样蛋白PET成像;与AD相关的CSF/血液生物标志物, 炎症和运动;以及两次全面的记忆/认知测试,间隔24- 个月目标2类似于人类项目,将确定自愿车轮运行PA的影响 在AD的新型转基因小鼠模型中, 与APPPS 1(APPPS 1; APOE 3/3和APPPS 1; APOE 4/4)及对照菌株杂交。关键指标 包括:TREM 2+细胞、促炎标志物表达、脑Aβ42和空间记忆能力。 总之,这些互补的人类和动物研究将提供对潜在机制的关键见解 将APOE基因型、运动、炎症、AD脑病理和认知联系起来, 有针对性的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce T Lamb其他文献

The PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events
  • DOI:
    10.1186/1750-1326-4-14
  • 发表时间:
    2009-03-16
  • 期刊:
  • 影响因子:
    17.500
  • 作者:
    Kiran Bhaskar;Megan Miller;Alexandra Chludzinski;Karl Herrup;Michael Zagorski;Bruce T Lamb
  • 通讯作者:
    Bruce T Lamb
Right sizing funding for Alzheimer's disease
  • DOI:
    10.1186/alzrt76
  • 发表时间:
    2011-01-01
  • 期刊:
  • 影响因子:
    7.600
  • 作者:
    Todd E Golde;Bruce T Lamb;Douglas Galasko
  • 通讯作者:
    Douglas Galasko

Bruce T Lamb的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce T Lamb', 18)}}的其他基金

Deciphering the role of CX3CR1 in Modulating Mechanisms of Amyloid driven Neurodegeneration in Alzheimer's Disease (Diversity Supplement)
破译 CX3CR1 在阿尔茨海默氏病淀粉样蛋白驱动的神经变性调节机制中的作用(多样性补充)
  • 批准号:
    10524900
  • 财政年份:
    2020
  • 资助金额:
    $ 153.32万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10250434
  • 财政年份:
    2019
  • 资助金额:
    $ 153.32万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10684136
  • 财政年份:
    2019
  • 资助金额:
    $ 153.32万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10017136
  • 财政年份:
    2019
  • 资助金额:
    $ 153.32万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center
IUSM 阿尔茨海默病药物研发中心
  • 批准号:
    10851513
  • 财政年份:
    2019
  • 资助金额:
    $ 153.32万
  • 项目类别:
Enzymatic substrates for HTS: IUSM Alzheimer's Disease Drug Discovery Center
HTS 的酶底物:IUSM 阿尔茨海默病药物发现中心
  • 批准号:
    10171202
  • 财政年份:
    2019
  • 资助金额:
    $ 153.32万
  • 项目类别:
IUSM Alzheimer's Disease Drug Discovery Center: PTC Software
IUSM 阿尔茨海默病药物研发中心:PTC 软件
  • 批准号:
    10198429
  • 财政年份:
    2019
  • 资助金额:
    $ 153.32万
  • 项目类别:
IU/JAX/Pitt MODEL-AD: MAPT-GR
IU/JAX/皮特 模型-AD:MAPT-GR
  • 批准号:
    10198518
  • 财政年份:
    2016
  • 资助金额:
    $ 153.32万
  • 项目类别:
Administrative and Coordination Core
行政及协调核心
  • 批准号:
    10402548
  • 财政年份:
    2016
  • 资助金额:
    $ 153.32万
  • 项目类别:
Administrative and Coordination Core
行政及协调核心
  • 批准号:
    10590446
  • 财政年份:
    2016
  • 资助金额:
    $ 153.32万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 153.32万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 153.32万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 153.32万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 153.32万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 153.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 153.32万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 153.32万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 153.32万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 153.32万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 153.32万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了